Rxivist logo

Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo

By Alexandra Schäfer, Frauke Muecksch, Julio C. C. Lorenzi, Sarah R. Leist, Melissa Cipolla, Stylianos Bournazos, Fabian Schmidt, Anna Gazumyan, Ralph S. Baric, Davide F. Robbiani, Theodora Hatziioannou, Jeffrey V. Ravetch, Paul D. Bieniasz, Michel C. Nussenzweig, Timothy P. Sheahan

Posted 15 Sep 2020
bioRxiv DOI: 10.1101/2020.09.15.298067

SARS-CoV-2, the causative agent of COVID-19, is responsible for over 24 million infections and 800,000 deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a mouse adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). In vitro antibody neutralization potency did not uniformly correlate with in vivo activity, and some hu-mAbs were more potent in combination in vivo . Analysis of antibody Fc regions revealed that binding to activating Fc receptors is essential for optimal protection against SARS-CoV-2 MA. The data indicate that hu-mAb protective activity is dependent on intact effector function and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 977 times
  • Download rankings, all-time:
    • Site-wide: 14,413 out of 106,159
    • In microbiology: 963 out of 9,238
  • Year to date:
    • Site-wide: 2,989 out of 106,159
  • Since beginning of last month:
    • Site-wide: 753 out of 106,159

Altmetric data


Downloads over time

Distribution of downloads per paper, site-wide


PanLingua

Sign up for the Rxivist weekly newsletter! (Click here for more details.)


News